Inhibitory effects of aclarubicin on nitric oxide production in aortic smooth muscle cells and macrophages

Biochemical Pharmacology

Volumn 59, Issue 6, 2000, Pages 719-726

  Wakabayashi, Ichiro ^a   Mayer, Bernd ^b   Groschner, Klaus ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Aclarubicin; Cytotoxicity; Gene transcription; Inducible nitric oxide synthase; Macrophage; Vascular smooth muscle cell

Indexed keywords

ACLARUBICIN; CYCLOHEXIMIDE; INTERLEUKIN 1BETA; N(G) METHYLARGININE; NITRIC OXIDE;

ANIMAL CELL; AORTA; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSCRIPTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ACLARUBICIN; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AORTA; CELL DIVISION; CELLS, CULTURED; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; ENZYME INHIBITORS; MACROPHAGES; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 0033976212     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00358-5     Document Type: Article

References (22)

1. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs. 54:(Suppl 4):1997;1-7.
2. Jacobs P. Myelodysplasia and the leukemias. Dis Mon. 43:1997;505-597.
3. Parrillo J.E., Parker M.M., Natanson C., Suffredini A.F., Danner R.L., Cunnion R.E., Ognibene F.P. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 113:1990;227-242.
4. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide Physiology, pathophysiology, and pharmacology . Pharmacol Rev. 43:1991;109-142.
5. Thiemermann C. The role of the L-arginine Nitric oxide pathway in circulatory shock . Adv Pharmacol. 28:1994;45-79.
6. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., Stevens K., Xie Q.W., Sokol K., Hutchinson N., Chen H., Mudgett J.S. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 81:1995;641-650.
7. Nathan C.F., Hibbs J.B. Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 3:1991;65-70.
8. Anthony L.S., Morrissey P.J., Nano F.E. Growth inhibition of Francisella tularensis live vaccine strain by IFN-γ-activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J Immunol. 148:1992;1829-1834.
9. Pacelli R., Wink D.A., Cook J.A., Krishna M.C., DeGraff W., Friedman N., Tsokos M., Samuni A., Mitchell J.B. Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med. 182:1995;1469-1479.
10. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J Exp Med. 178:1993;2249-2254.
11. Wakabayashi I., Sakamoto K., Hatake K. Inhibitory effect of aclarubicin on endothelium-dependent relaxation of rat aorta. Pharmacol Toxicol. 68:1991;187-191.
12. Wakabayashi I., Hatake K., Yoshimoto S., Sakamoto K. Inhibitory effects of daunorubicin on endothelium-dependent vasorelaxing response to acetylcholine of rat aorta. J Pharm Pharmacol. 46:1994;296-299.
13. Sakai T., Muramatsu I., Hayashi N., Ishii Y. Inhibition of NO synthase induction by an anticancer drug 4′-epi-doxorubicin in rats. Gen Pharmacol. 27:1996;1367-1372.
14. Luo D., Vincent S.R. Inhibition of nitric oxide synthase by antineoplastic anthracyclines. Biochem Pharmacol. 47:1994;2111-2112.
15. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 50:1971;172-186.
16. Mayer B., Klatt P., Werner E.R., Schmidt K. Molecular mechanisms of inhibition of porcine brain nitric oxide synthase by the antinociceptive drug 7-nitro-indazole. Neuropharmacology. 33:1994;1253-1259.
17. Lind D.S., Kontaridis M.I., Edwards P.D., Josephs M.D., Moldawer L.L., Copeland E.M. III. Nitric oxide contributes to adriamycin's antitumor effect. J Surg Res. 69:1997;283-287.
18. Joshi P., Vig P.J., Veerisetty V., Cameron J.A., Sekhon B.S., Desaiah D. Increase in brain nitric oxide synthase activity in daunorubicin-treated rats. Pharmacol Toxicol. 78:1996;99-103.
19. Komiyama T., Kikuchi T., Sugiura Y. Interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C, with NADPH-cytochrome P-450 reductase, xanthine oxidase and oxygen. J Pharmacobiodyn. 9:1986;651-664.
20. Jensen P.B., Sorensen B.S., Demant E.J., Sehested M., Jensen P.S., Vindelov L., Hansen H.H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res. 50:1990;3311-3316.
21. Chabner BA, Allegra CJ, Curt GA and Calabresi P, Antineoplastic agents. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (Eds. Hardman JG, Limberd LE, Molinoff PB, Ruddon RW and Gilman AG), pp. 1233-1287. McGraw-Hill, Health Professions Division, New York, 1996.
22. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:1998;83-106.